In contrast, promoting RIPK1 activation by removing pro-survival phosphorylation checkpoints (pS25) while enhancing pro-death phosphorylation (pS166) offers a more targeted approach that holds the potential to bypass tumor survival pathways. The gene discussed is RIPK1; the disease is neoplasm.